GLP1R and myocardial infarction: Our analysis, based on > 33,000 patients and 4000 cardiovascular events, provided robust reassurance about the cardiovascular safety of GLP1R agonists, showing no increase in risks for hospitalization for heart failure and myocardial infarction.